Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Yondelis trabectedin regulatory update

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending against the use of Yondelis trabectedin from PharmaMar in combination with pegylated

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE